Tranexamic Acid for Dark Marks: What the Evidence Does and Does Not Show
Tranexamic acid has real trial data behind it for post-inflammatory hyperpigmentation, but most of that data compares it to another active rather than to doing nothing.
Does tranexamic acid actually fade dark marks, or is it borrowed hype from melasma treatment? It is a legitimate active with a real mechanism and real trial data, though most of what has been tested is how it stacks up against another treatment rather than against a placebo. Worth separating the two questions before getting excited about either.
What it is actually doing in the skin
Tranexamic acid was developed as a drug to stop bleeding, and its route into skincare runs through that original mechanism. A 2026 literature review explains it plainly: "By preventing plasminogen from being converted to plasmin, which is involved in the breakdown of fibrin, tranexamic acid is known to reduce bleeding through its antifibrinolytic action. Because of its strong plasmin inhibitory action, TXA is believed to have anti-inflammatory, antimelanogenic, and antiangiogenic properties." 1 The plasmin pathway it blocks is also involved in triggering melanocytes to ramp up pigment production, so the same mechanism that stops a bruise from bleeding also appears to turn down the signal that tells skin to darken.
The trial that actually tested it on acne marks
A 2023 single-blinded randomized clinical trial put topical tranexamic acid head to head against azelaic acid, an already-established option, in patients with post-acne PIH. "A 12-week single-blind randomized clinical experiment was conducted by Sobhan et al. on patients with post-acne PIH. Two groups of patients (30 in each group) received twice-daily applications of 20% azelaic acid (AZA) cream and 5% TXA solution, respectively." 2 Both groups improved by a comparable amount over the 12 weeks. Tranexamic acid's edge in this trial was not that it worked better, it was that it was gentler in the first month, with fewer treatment-related side effects reported in that early window than the azelaic acid group experienced.
Read the design before you read the result
This is the honest caveat that gets left out of most marketing copy. The Sobhan trial did not include an untreated or placebo arm, so it cannot tell you that tranexamic acid beats doing nothing, only that it performs comparably to another active ingredient that already has its own evidence base. A 2026 review of emerging PIH therapies frames tranexamic acid the same way, as one option among several rather than a standout: "Emerging therapies such as cysteamine and TXA expand the range of treatment options for PIH, providing effective and safe alternatives to HQ in skin of color." 3 An alternative to hydroquinone is a genuinely useful thing to be, and it is a more modest claim than "erases dark spots," which is closer to what gets printed on a bottle.
Where the evidence still falls short
The literature review cited above is equally direct about the gap: more high-quality randomized trials are still needed to settle the right route of administration, the right duration, and the safety of long-term use, since most of the strongest tranexamic acid data to date comes from oral and injected forms treating melasma rather than topical forms treating acne marks specifically. A broader review of PIH notes it sits in a crowded field of "topical agents, chemical peels, and energy-based devices," 4 and tranexamic acid is one credible entry in that field rather than a category of its own.
The honest summary
Topical tranexamic acid has a plausible mechanism, a real head-to-head trial showing it performs comparably to azelaic acid with a gentler early safety profile, and a research community that openly says more work is needed before its exact dosing and duration are settled. That is a genuinely useful ingredient to know about. It is not, on the evidence available right now, proven to outperform every alternative, and anyone telling you otherwise is reading the marketing rather than the trial.
References
- AlJabr A, AlAnazi AMI, AlEtebi RA. Tranexamic acid for hyperpigmentation disorders: a literature review on efficacy and safety in melasma and PIH. J Cosmet Dermatol. 2026, 25(2):e70692. doi.org/10.1111/jocd.70692
- Sobhan M, Talebi-Ghane E, Poostiyan E. A comparative study of 20% azelaic acid cream versus 5% tranexamic acid solution for the treatment of postinflammatory hyperpigmentation in patients with acne vulgaris: a single-blinded randomized clinical trial. J Res Med Sci. 2023, 28:18. PMID 37213446. doi.org/10.4103/jrms.jrms_443_22
- Persson C, Desai R, Manikkuttiyil C, Multani H, Lirio R, Nueva M, Hesari R, Gupta A. Post-inflammatory hyperpigmentation in skin of color: emerging therapies and treatment algorithms. Cureus. 2026, 18. PMID 42153065. doi.org/10.7759/cureus.107234
- Kaufman BP, Aman T, Alexis AF. Postinflammatory hyperpigmentation: epidemiology, clinical presentation, pathogenesis and treatment. Am J Clin Dermatol. 2018, 19(4):489-503. PMID 29222629. doi.org/10.1007/s40257-017-0333-6
